We believe the following reasons may explain the discrepancy between our findings regarding clinical benefit from immunotherapies in patients with APC/CTNNB1-mutant melanoma and previous preclinical or translational observations [11, 31]. The gene discussed is CTNNB1; the disease is melanoma.